Document Detail

The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
MedLine Citation:
PMID:  23325019     Owner:  NLM     Status:  Publisher    
Left ventricular dysfunction from anticancer drugs has emerged as a relevant problem in the clinical and scientific communities. Anthracycline toxicity has always been the most relevant, but with the increasing use of biological targeted therapies in treatment protocols, with an increasing number of cancer survivors, new toxicities have been increasing in more recent years. Cardiomyopathy after ErbB2 inhibitors has been intensively studied. Another important class of biological anticancer drugs are vascular endothelial growth factor (VEGF) inhibitors. VEGF signalling is crucial for vascular growth, but it also has a major impact on myocardial function. Also, it is important to note that such angiogenesis inhibitors are multitargeted in most cases, and can produce a broad spectrum of cardiovascular side effects. Here we review the mechanisms and pathophysiology of the most significant cardiotoxic effects of antiangiogenic drugs, and particular attention is drawn to LV dysfunction, discussing the assessment and management on the basis of the most recent cardio-oncological findings and heart failure guidelines.
Carlo G Tocchetti; Giuseppina Gallucci; Carmela Coppola; Giovanna Piscopo; Clemente Cipresso; Carlo Maurea; Aldo Giudice; Rosario V Iaffaioli; Claudio Arra; Nicola Maurea
Related Documents :
16426869 - The use of levetiracetam in refractory status epilepticus.
12445959 - Overtreatment in adults with epilepsy.
23496079 - Applications of nuclear quadrupole resonance spectroscopy in drug development.
24646729 - Comparability and imprecision of 8 frequently used commercially available immunoassays ...
12151119 - New strategies for the identification of drugs to prevent the development or progressio...
6430019 - The effects of various antiepileptic drugs on e-shock-induced amnesia in mice: dissocia...
25253389 - Poised epigenetic states and acquired drug resistance in cancer.
18624679 - Potential role of intestinal first-pass metabolism in the prediction of drug-drug inter...
17192799 - Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: stat...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-16
Journal Detail:
Title:  European journal of heart failure     Volume:  -     ISSN:  1879-0844     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Cardiology, National Cancer Institute, Pascale Foundation, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with sever...
Next Document:  Parenting influences on Latino children's social competence in the first grade: parental depression ...